OPKO Pharmaceuticals, LLC
$740.7K 6,592 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Intera Oncology, Inc
Intera Oncology, Inc reported $739,675.07 across General Payments, Research, and Ownership to 313 physicians and teaching hospitals across 314 transactions.
- $739.7K Above-median payer
- All-tracks total
- 314 Above-median volume
- Transactions
- 313 Above-median reach
- Recipients
- +$56.8K
- General Payments vs PY2023
Intera Oncology, Inc reported $739,675.07 across all CMS Open Payments tracks (General + Research + Ownership) to 313 physicians and teaching hospitals in Program Year 2024 - ranking #685 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $90,946.57, averaging $2.4K per recipient.
How Intera Oncology, Inc's $739.7K all-tracks total breaks down
Intera Oncology, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
17/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer intera-oncology-inc Intera Oncology, Inc
$739.7K · #685/1,925 · 0.0% industry · PY2024
- TOT $739.7K
- RANK #685
- SHARE 0.0%
- TXN 314
- RCP 313
- CAT 2
- GEN $90.9K
- ΔGEN +$56.8K
- TOP1 20.0%
- PY 2024
Volume peers
Nearest volume peer: OPKO Pharmaceuticals, LLC ($740.7K)
Intera Oncology, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Intera Oncology, Inc's CMS-reported General Payments increased by $56.8K (+166.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTERA ONCOLOGY, INCPY2023: INTERA ONCOLOGY, INCPY2024: Intera Oncology, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $34,123.60
- PY2024
- $90,946.57
What the Data Shows for Intera Oncology, Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Intera Oncology, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $59.1K across 51 transactions, 64.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Intera Oncology, Inc's 2-category general-payment breakdown at $59.1K, 64.9% of the reported total.
How Intera Oncology, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $59.1K | 51 | 64.9% |
| Food and Beverage | $31.9K | 262 | 35.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $46,319.32 (50.9%) of $90,946.57 in this company's General Payments records across 238 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Intera Oncology, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Louise Connell
$18,194.33 across 10 reported transactions
- 2
Devika Rao
$10,999.99 across 8 reported transactions
- 3
Jason Alfred Castellanos
$6,375.00 across 3 reported transactions
- 4
Cornelius Thiels
$5,500.00 across 2 reported transactions
- 5
Nancy Kemeny
$5,250.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Intera Oncology, Inc ranks #685 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,162 of 1,838 by HHI (bottom 37% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Tokuyama Dental America Inc. : $79.2K total payments, HHI 733
- Samsung Bioepis Co., Ltd. : $85.2K total payments, HHI 728
- PharmaEssentia USA Corporation : $714.5K total payments, HHI 727
- Exactech, Inc. : $8.1M total payments, HHI 722
- Guerbet LLC : $589.2K total payments, HHI 722
- Valley Contax, Inc. : $90.4K total payments, HHI 721
- Intera Oncology, Inc (this company) : $90.9K total payments, HHI 720
- EMD Serono Research & Development Institute, Inc. : $320.3K total payments, HHI 719
- Brainlab, Inc. : $119.2K total payments, HHI 717
- Central Indiana URS Consumables, LLC : $214.2K total payments, HHI 714
- Guard Medical Inc. : $77.8K total payments, HHI 712
- Ocular Therapeutix, Inc. : $1.8M total payments, HHI 711
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Intera Oncology, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Intera Oncology, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Intera Oncology, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Gyrus ACMI, Inc.
$738.6K 91 recipients
Compare payment profiles
Cardiva Medical, Inc.
$741.8K 7,304 recipients
Compare payment profiles
La Jolla Pharmaceutical Company
$746.9K 3,634 recipients
Compare payment profiles
TightLine Development, LLC
$750.0K 1 recipients
Compare payment profiles
Carl Zeiss Meditec USA, Inc.
$719.3K 2,435 recipients
Compare payment profiles
Put this to use
Intera Oncology, Inc ranks #685 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Intera Oncology, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.